Celgene Corp. (CELG)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Mark J. Alles
Employees:
8,852
86 MORRIS AVENUE, SUMMIT, NJ, 07901
(908)673-9000

• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Celgene Corp. is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. Its targeting areas include intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. The company's products include Revlimid, Vidaza, Thalomid, Pomalyst/Imnovid, Abraxane, and Istodax. Celgene was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.

Data derived from most recent annual or quarterly report
Market Cap 76.714 Billion Shares Outstanding708.74 Million Avg 30-day Volume 16.189 Million
P/E Ratio12.3196 Dividend Yield0.0 EPS6.8
Price to Revenue4.2657 Debt to Equity1.637 EBITDA7.957 Billion
Price to Book Value5.9932 Operating Margin46.4727 Enterprise Value81.329 Billion
Current Ratio2.886 EPS Growth1.051 Quick Ratio2.649
1 Yr BETA 0.5749 52-week High/Low 0.0 / Profit Margin34.6249
Operating Cash Flow Growth80.6066 Altman Z-Score3.5087 Free Cash Flow to Firm 6.707 Billion
View SEC Filings from CELG instead.

View recent insider trading info

Celgene Corp. YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding CELG (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CELG

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2019-11-22 by VESSEY RUPERT
  • 4: filed on 2019-11-22 by AHMED NADIM
  • 4: filed on 2019-11-22 by AHMED NADIM
  • 4: filed on 2019-11-22 by ALLES MARK J
  • 4: filed on 2019-11-22 by ALLES MARK J
  • 4: filed on 2019-11-22 by ELKINS DAVID V
  • 4: filed on 2019-11-22 by CURRAN TERRIE
  • 4: filed on 2019-11-22 by CURRAN TERRIE
  • 4: filed on 2019-11-22 by BILLER JONATHAN
  • 4: filed on 2019-11-22 by BILLER JONATHAN

    • Events (8k)

  • 8-K: filed on 2019-11-22:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-11-20:
    Item 1.02: Termination of a Material Definitive Agreement
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-10-31:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-08-26:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-07-30:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-04-12:
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-03-26:
    Item 8.01: Other Events
  • 8-K: filed on 2019-03-08:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-01-31:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K/A: filed on 2019-01-25:
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    COX CARRIE SMITH

    • Director
    		 No longer subject to file 2019-11-20 0

    MARIO ERNEST

    • Director
    		 No longer subject to file 2019-11-20 0

    CASEY MICHAEL D

    • Director
    		 No longer subject to file 2019-11-20 0

    WEILAND JOHN H

    • Director
    		 No longer subject to file 2019-11-20 0

    BONNEY MICHAEL W

    • Director
    		 No longer subject to file 2019-11-20 0

    BARKER RICHARD W

    • Director
    		 No longer subject to file 2019-11-20 0

    LOUGHLIN JAMES J

    • Director
    		 No longer subject to file 2019-11-20 0

    FRIEDMAN MICHAEL A

    • Director
    		 No longer subject to file 2019-11-20 0

    ELKINS DAVID V EVP, CHIEF FINANCIAL OFFICER

    • Officer
    		 No longer subject to file 2019-11-20 0

    BISHOP HANS EDGAR

    • Director
    		 No longer subject to file 2019-11-20 0

    HALL PATRICIA HEMINGWAY

    • Director
    		 No longer subject to file 2019-11-20 0

    ALLES MARK J CEO, CHAIRMAN OF BOARD

    • Officer
    • Director
    		 No longer subject to file 2019-11-20 0

    HALLER JULIA A

    • Director
    		 No longer subject to file 2019-11-20 0

    VESSEY RUPERT PRES., RESEARCH AND EARLY DEV.

    • Officer
    		 No longer subject to file 2019-11-20 0

    CURRAN TERRIE PRES., GLBL INFLAM. AND IMMUN.

    • Officer
    		 No longer subject to file 2019-11-20 0

    AHMED NADIM PRES., GLOBAL HEM. AND ONC.

    • Officer
    		 No longer subject to file 2019-11-20 0

    BILLER JONATHAN EVP AND GENERAL COUNSEL

    • Officer
    		 No longer subject to file 2019-11-20 0

    REICIN ALISE PRES., GLOBAL CLINICAL DEV.

    • Officer
    		 No longer subject to file 2019-11-20 0

    KELLOGG PETER N SEE REMARKS

    • Officer
    		 69,974 2018-07-30 0

    MASOUDI GERALD SEE REMARKS

    • Officer
    		 13,698 2018-06-01 0

    KAPLAN GILLA

    • Director
    		 76,301 2018-05-18 0

    SMITH SCOTT ANDREW SEE REMARKS

    • Officer
    		 52,207 2018-02-17 0

    HUGIN ROBERT J SEE REMARKS

    • Officer
    • Director
    		 1,025,347 2017-12-31 0

    PEHL MICHAEL F. SEE REMARKS

    • Officer
    		 2,363 2017-07-28 0

    FOUSE JACQUALYN A SEE REMARKS

    • Officer
    • Director
    		 0 2017-02-14 0

    KARSEN PERRY A SEE REMARKS

    • Officer
    		 No longer subject to file 2015-12-31 0

    DANIEL THOMAS O SEE REMARKS

    • Officer
    		 No longer subject to file 2015-12-31 0

    STEIN LAWRENCE V SEE REMARKS

    • Officer
    		 14,568 2015-05-14 0

    DRAKE RODMAN L

    • Director
    		 26,180 2014-06-12 0

    MORIARTY THOMAS M SEE REMARKS

    • Officer
    		 0 2012-06-01 0

    BURTON GRAHAM SEE REMARKS

    • Officer
    		 0 2012-01-30 0

    VAN HOEK ANDRE CONTROLLER AND CAO

    • Officer
    		 0 2011-10-31 0

    ROBB WALTER L

    • Director
    		 No longer subject to file 2011-06-15 0

    BARER SOL J

    • Director
    		 753,473 2011-01-13 0

    BROUWER AART SEE REMARKS

    • Officer
    		 No longer subject to file 2010-12-31 0

    GRYSKA DAVID W CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2010-07-13 0

    HAYES ARTHUR H JR

    • Director
    		 0 2010-02-09 0

    MORGAN RICHARD C E

    • Director
    		 116,732 2008-07-28 0

    BOWMAN JACK L

    • Director
    		 4,625 2007-09-17 0

    JACKSON JOHN W

    • Director
    		 1,352,638 2006-06-30 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments